Addressing this unmet need head-on is critical, and while there are pharmaceutical treatments for the excessive sleepiness associated with OSA, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease." Results from the SURMOUNT-OSA trial will be presented at the American Diabetes Association Scientific Sessions on June 21 at 3:45 p.m
Latest News Unpacking the Mysteries of the Microbiome Read More ArtMedicas concierge care offers personalized benefits, including direct communication, after-hours availability, and convenient email or text access for non-urgent concerns
By middle age, your natural NAD+ levels are significantly lower than in your 20s, and this decline accelerates with chronic stress, poor diet, or illness
Can non-diabetic patients take GLP-1 medications
Then go back to your normal schedule
The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieved a mean weight reduction of 20.9% over 72 weeks compared with 3.1% for placebo [2]
